Takeaway

• The combined clinical cell-cycle risk (CCR) score derived from both clinical and genetic factors can identify patients with intermediate- and high-risk localized prostate cancer who may not require androgen deprivation therapy (ADT).

Why this matters

• Findings suggest that patients with CCR <2.112 experience no additional benefit from combining ADT with...